Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort.

Shee, Kevin; Washington, Samuel L; Cowan, Janet E; de la Calle, Claire M; Baskin, Avi S; Chappidi, Meera R; Escobar, Domenique; Nguyen, Hao G; Cooperberg, Matthew R; Carroll, Peter R

Shee, Kevin; Washington, Samuel L; Cowan, Janet E; de la Calle, Claire M; Baskin, Avi S; Chappidi, Meera R; Escobar, Domenique; Nguyen, Hao G; Cooperberg, Matthew R; Carroll, Peter R.

Afiliación

Shee K; Department of Urology, UCSF, San Francisco, California.
Washington SL; Department of Urology, UCSF, San Francisco, California.
Cowan JE; Department of Epidemiology & Biostatistics, UCSF, San Francisco, California.
de la Calle CM; Department of Urology, UCSF, San Francisco, California.
Baskin AS; Department of Urology, UCSF, San Francisco, California.
Chappidi MR; Department of Urology, UCSF, San Francisco, California.
Escobar D; Department of Urology, UCSF, San Francisco, California.
Nguyen HG; Department of Urology, UCSF, San Francisco, California.
Cooperberg MR; Department of Urology, UCSF, San Francisco, California.
Carroll PR; Department of Urology, UCSF, San Francisco, California.

J Urol ; 209(1): 198-207, 2023 01.

Article en En | MEDLINE | ID: mdl-36067374

Asunto(s)

Antígeno Prostático Específico; Neoplasias de la Próstata; Humanos; Masculino; Neoplasias de la Próstata/cirugía

Palabras clave

prostatectomy; prostatic neoplasms; watchful waiting

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: J Urol Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google